Sign In
Buy CNSP
$5.24
+0.320 (+6.50%)
At Close: Jun 03, 2026
Nasdaq Scheduled Resumption in CNS Pharmaceuticals Inc.
08:53pm, Wednesday, 27'th May 2020
NEW YORK, May 27, 2020 -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading in CNS Pharmaceuticals Inc. (Nasdaq: CNSP) is scheduled to resume on Thursday, May 28,.
CNS Provides Update on Development Agreement for WP1122
08:10pm, Wednesday, 27'th May 2020
CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and
AIDP Partners With Verdant Oasis | WholeFoods Magazine
02:00pm, Tuesday, 26'th May 2020
City of Industry, CA—AIDP has announced in a press release that, effective immediately, it will be distributing Verdant Oasis European Hemp products. Verdant Oasis grows and processes full-spectrum
Jan Jambon annonce que l’interdiction de séjour dans les résidences secondaires va être levée
03:06pm, Wednesday, 20'th May 2020
Il y a un consensus entre les membres qui siègent au CNS, affirme le ministre-président flamand.
Avrio Health L.P., a subsidiary of Purdue Pharma L.P. (“Purdue”), has initiated a program to evaluate the potential safety and virucidal effectiveness
Nasdaq Halts CNS Pharmaceuticals Inc.
12:48pm, Monday, 18'th May 2020
NEW YORK, May 18, 2020 -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that the trading halt status in CNS Pharmaceuticals Inc. (Nasdaq: CNSP) was changed to "additional.
UPDATE: Moleculin Biotech, CNS Pharma shares remain halted on Nasdaq
12:08pm, Monday, 18'th May 2020
Moleculin Biotech Inc. and CNS Pharmaceuticals Inc. said Monday their shares remain halted on Nasdaq with the exchange seeking additional information from each company. Shares werehalted temporarily
CNS Announces Nasdaq Trading Halt Pending Receipt of Additional Information
12:00pm, Monday, 18'th May 2020
CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and
“Cell Pores” Discovery Offers New Hope for Millions With Brain and Spinal Cord Injuries
03:00pm, Thursday, 14'th May 2020
https://youtu.be/_QRtxLk3yVQ New research from a team of international scientists shows how swelling associated with brain and spinal cord injury can be stopped using a drug already licensed for human
AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020
12:00am, Thursday, 14'th May 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today an
Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q1 2020 Results - Earnings Call Transcript
11:10pm, Tuesday, 12'th May 2020
Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Q1 2020 Earnings Conference Call May 12, 2020 4:30 p.m. ET Company Participants Jim Mazzola - SVP, Communication
Coronavirus update: Global case tally tops 4.1 million; South Korea reports cluster from Seoul nightclubs, Wuhan has 4 new cases
04:03pm, Monday, 11'th May 2020
The number of cases of COVID-19 rose above 4.1 million on Monday, as South Korea reported a new cluster stemming from Seoul’s nightclub district and China...
Reprise des visites immobilières: comment les mener en toute sécurité?
02:24pm, Monday, 11'th May 2020
Les visites immobilières ont repris le 11 mai. Voici comment organiser une visite "safe".
CNS Provides Additional Comments Regarding Trading Halt
12:00pm, Monday, 11'th May 2020
CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and
Moleculin Biotech did not solicit claims third parties made about a COVID-19 drug candidate that led to an SEC halt
11:44am, Monday, 11'th May 2020
Moleculin Biotech Inc. undefined said Monday it did not solicit or have any advance knowledge about claims made by third parties about its drug candidate...
